U.S. begins large clinical trial to test immune modulators for COVID-19 treatment


WASHINGTON, Oct. 16 (Xinhua) -- The U.S. National Institutes of Health (NIH) has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19, said a statement of the agency on Friday.

Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation. The clinical trial aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays.

The trial, known as ACTIV-1 Immune Modulators, will determine if the therapeutics are able to restore balance to an overactive immune system, said the NIH.

The trial expects to enroll approximately 2,100 hospitalized adults with moderate to severe COVID-19 at medical facilities in the United States and Latin America.

All participants in the trial will receive remdesivir, which is the current standard of care treatment of hospitalized patients with COVID-19. Convalescent plasma and dexamethasone will be allowed at the discretion of the site investigator and in accordance with national guidelines, said the NIH.

The participants will be randomly assigned to receive a placebo or one of the immune modulators as an add-on treatment. The trial will study the different combination treatment regimens with respect to illness severity, recovery speed, mortality and hospital resource utilization, according to the NIH.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

100% readers found this article insightful

Next In World

Berlin hands transcripts to Moscow for probe into Navalny poisoning
Ally of poisoned Kremlin critic Navalny jailed in Moscow for extremism
Distrust, division and doubt cloud Palestinian election call
Major European powers rebuke Iran over uranium metal plans
Tennis: COVID cases on player flights leave Australian Open buildup in disarray
UK eyes one-off COVID-19 grant instead of permanent benefit hike - Times
In visit to Central African Republic, French general says situation not same as 2013
U.S. state capitals on edge for armed protests as Trump presidency nears end
Explainer: Can Trump pardon himself? Would the courts reject the move?
Iran fires long-range missiles into Indian Ocean in military drill - media

Stories You'll Enjoy